Director/PDMR Shareholding
20 March 2020 07:00 GMT
Transaction by Person Discharging Managerial Responsibilities
Disclosure under Article 19 of the EU Market Abuse Regulation
AstraZeneca PLC (the Company) announced that, on 19 March 2020, it was notified by Tony Mok, a Non-Executive Director of the Company, that, on 18 March 2020, Mr Mok purchased 1,000 of the Company's American Depositary Shares (ADSs) at a price of $38.32 per ADS. Two ADSs are equivalent to one Ordinary Share of $0.25 in the Company.
The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Tony Mok | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Non-Executive Director | ||||
| b) | Initial notification /Amendment | Initial notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | AstraZeneca PLC | ||||
| b) | LEI | PY6ZZQWO2IZFZC3IOL08 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument Identification code | AstraZeneca PLC American Depositary Shares CUSIP: 046353108 | ||||
| b) | Nature of the transaction | Purchase of AstraZeneca PLC American Depositary Shares | ||||
| c) | Price(s) and volume(s) |
|
||||
| d) | Aggregated information - Aggregated volume - Price | Not applicable - single transaction | ||||
| e) | Date of the transaction | 18 March 2020 | ||||
| f) | Place of the transaction | NYSE | ||||
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
| Media Relations | ||
| Gonzalo Viña | +44 203 749 5916 | |
| Rob Skelding | Oncology | +44 203 749 5821 |
| Rebecca Einhorn | Oncology | +1 301 518 4122 |
| Matt Kent | BioPharmaceuticals | +44 203 749 5906 |
| Angela Fiorin | BioPharmaceuticals | +44 1223 344 690 |
| Jennifer Hursit | Other | +44 203 749 5762 |
| Christina Malmberg Hägerstrand | Sweden | +46 8 552 53 106 |
| Michele Meixell | US | +1 302 885 2677 |
| Investor Relations | ||
| Thomas Kudsk Larsen | +44 203 749 5712 | |
| Henry Wheeler | Oncology | +44 203 749 5797 |
| Christer Gruvris | BioPharmaceuticals(Cardiovascular, Metabolism) | +44 203 749 5711 |
| Nick Stone | BioPharmaceuticals (Renal) Environmental, Social and Governance | +44 203 749 5716 |
| Josie Afolabi | BioPharmaceuticals (Respiratory) | +44 203 749 5631 |
| Tom Waldron | Other medicines | +44 7385 033 717 |
| Craig Marks | FinanceFixed income | +44 7881 615 764 |
| Jennifer Kretzmann | Corporate accessRetail investors | +44 203 749 5824 |
| US toll-free | +1 866 381 72 77 |
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.